Employees: 17
Size Relmada Therapeutics (RLMD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $305M, the 3068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.85 on 18 Nov 2026.
Performance Over six months the shares fell 60.2%, against -20.9% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| EBITDA | -$67.9M | -$59.1M | -$83.9M | -$104M | -$161M |
| Net income | -$65.7M | -$57.4M | -$80.0M | -$98.8M | -$157M |
| Free cash flow | -$51.9M | -$45.8M | -$51.8M | -$51.7M | -$104M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $0 | $0 | $0 | $0 | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RLMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.0% | -9.4% | 2nd lowest of 21 |
| 6-month return | -60.2% | -20.9% | lowest of 21 |
| Distance from 52-week high | -64.3% | -37.5% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics RLMD | United States | $305M | -60% | n/a | n/a | n/a | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $305M | -35% | +251% | -195% | 17.1× | n/a | n/a |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | 2.1× | 14.0% | +7.3% |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | 13.0× | 44.3% | +26.7% |
| Honz Pharmaceutical 300086.SZ | China | $299M | -40% | -23% | -54% | 7.3× | 56.0% | -12.8% |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | 5.6× | 27.5% | -6.4% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $297M | -30% | -3% | 7% | 2.3× | 4.6% | -0.3% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $296M | -21% | -32% | -58% | 4.8× | 1.4% | -4.9% |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | 3.4× | n/a | n/a |
| OBI Pharma 4174.TWO | Taiwan | $295M | +135% | -2% | -2,968% | 214.0× | n/a | n/a |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | 921.6× | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 3.1× | -16.8% | +5.4% |
| Shandong Sito Bio-technology 300583.SZ | China | $292M | -30% | +19% | 6% | 2.3× | 1.6% | +2.3% |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | 1.1× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 1.8× | 6.1% | +62.1% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | 21.4× | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | 6.2× | n/a | n/a |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | 7.4× | 14.3% | -14.0% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | 1.8× | -11.5% | +10.3% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | 1.4× | 9.2% | +6.5% |